Stock FRX FENNEC PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Market Closed - Toronto S.E.
Other stock markets
 20:59:59 17/07/2024 BST 		5-day change 1st Jan Change
9.1 CAD -0.55% Intraday chart for Fennec Pharmaceuticals Inc. +12.62% -39.97%
07-02 MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris MT
07-01 Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris
MT
Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down
MT
Fennec Pharmaceuticals Announces Management Change
GL
Fennec Pharmaceuticals Inc. Announces Executive Changes
CI
Fennec Announces Results of Annual Meeting
GL
HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating
MT
Fennec Pharmaceuticals : Corporate Presentation May 2024
PU
Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue
MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities
MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction
MT
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
GL
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing
MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FENC Stock
  4. FRX Stock
  5. News Fennec Pharmaceuticals Inc.